JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NAT INSTITUTE OF INFECTIOUS DISEASES has a total of 26 patent applications. It increased the IP activity by 300.0%. Its first patent ever was published in 2006. It filed its patents most often in Australia, Brazil and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are MEMGEN LLC, PEPTIMED INC and SYNTELLO INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 8 | |
#2 | Brazil | 3 | |
#3 | EPO (European Patent Office) | 3 | |
#4 | United States | 3 | |
#5 | Canada | 2 | |
#6 | Hungary | 1 | |
#7 | Israel | 1 | |
#8 | Mexico | 1 | |
#9 | New Zealand | 1 | |
#10 | Philippines | 1 | |
#11 | Singapore | 1 | |
#12 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Peptides | |
#5 | Analysing materials | |
#6 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Suzuki Tadaki | 10 |
#2 | Ainai Akira | 10 |
#3 | Hasegawa Hideki | 10 |
#4 | Miyazaki Takashi | 9 |
#5 | Kamishita Taizou | 9 |
#6 | Ato Manabu | 6 |
#7 | Adachi Yu | 6 |
#8 | Takahashi Yoshimasa | 6 |
#9 | Fukushima Akihisa | 3 |
#10 | Takaji Wakita | 3 |
Publication | Filing date | Title |
---|---|---|
US2019040415A1 | Cultured transgenic cell allowing growth of norovirus, and use thereof | |
BR112016021576A2 | anti-hepatitis c virus e2 protein antibody or antibody fragment that binds to antigen thereof, nucleic acid, and medicament; |